Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Retraction to: Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes (Diabetologia, (2018), 61, 2, (482-495), 10.1007/s00125-017-4469-y)

Purvis GSD. et al, (2025), Diabetologia

Drug repurposing screen identifies novel anti-inflammatory activity of sunitinib in macrophages.

Chaffey LE. et al, (2024), Eur J Pharmacol

OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity.

Purvis GSD. et al, (2024), Diabetes

Multityrosine kinase inhibitor sunitinib has anti-inflammatory activity in macrophages mediated via inhibition of NF-κB

Chaffey L. et al, (2023), BRITISH JOURNAL OF PHARMACOLOGY, 180, 536 - 537

OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity

Purvis G. et al, (2023)

A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages.

Rumianek AN. et al, (2022), Front Immunol, 13

Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues.

Sheikh MH. et al, (2022), FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 36

Bruton's tyrosine kinase (BTK) regulates myeloid cell recruitment during acute inflammation.

Purvis GSD. et al, (2021), Br J Pharmacol

A novel hCD68 CreERT(2) mouse strain for macrophage targeting in vivo

Rumianek A. et al, (2021), BRITISH JOURNAL OF PHARMACOLOGY, 178, 4949 - 4949

Novel anti-inflammatory activity of sunitinib malate identified in a macrophage drug-repurposing screen of FDA-approved medicines

Chaffey L. et al, (2021), BRITISH JOURNAL OF PHARMACOLOGY, 178, 4938 - 4939

Ly6Chi monocytes are metabolically reprogrammed in the blood during inflammatory stimulation allowing for macrophage lineage commitment

Purvis GSD. et al, (2021)

A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice.

Mohammad S. et al, (2021), Front Immunol, 12

Bruton’s tyrosine kinase (BTK) regulates myeloid cell recruitment during acute inflammation

Purvis G. et al, (2021)

X-LINKED IMMUNE DEFECT MICE ARE PROTECTED AGAINST SEPSIS-INDUCED CARDIAC DYSFUNCTION

O'Riordan C. et al, (2020), SHOCK, 53, 97 - 97

Inhibition of Bruton’s tyrosine kinase reduces NF-kB and NLRP3 inflammasome activity preventing insulin resistance and microvascular disease

Purvis G. et al, (2019)

Inhibition of NF-kappa B Pathway with IKK-16 or Linagliptin Attenuates the Cardiac Dysfunction Associated with Polymicrobial Sepsis in Mice with Preexisting Type 2 Diabetes Mellitus (T2DM)

Al Zoubi S. et al, (2018), DIABETES, 67

Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes.

Purvis GSD. et al, (2018), Diabetologia, 61, 482 - 495

Endogenous Annexin-A1 is a Protective Determinant in HFD-induced Insulin Resistance and Diabetic Nephropathy

Purvis GSD. et al, (2017), FASEB JOURNAL, 31

Endogenous annexin-A1 is a protective determinant in high-fat diet (HFD)-induced insulin resistance and diabetic nephropathy

Purvis GSD. et al, (2017), DIABETIC MEDICINE, 34, 26 - 26

Role of annexin-A1 on blood-brain barrier functionality

Purvis GSD. et al, (2017), DIABETIC MEDICINE, 34, 64 - 64

Load More

Include forthcoming?